Novartis AG (NYSE:NVS) Shares Purchased by Rothschild Investment LLC

Rothschild Investment LLC grew its position in Novartis AG (NYSE:NVS) by 0.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,682 shares of the company’s stock after purchasing an additional 101 shares during the quarter. Rothschild Investment LLC’s holdings in Novartis were worth $1,623,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Crestwood Advisors Group LLC increased its position in shares of Novartis by 9.7% during the fourth quarter. Crestwood Advisors Group LLC now owns 2,309 shares of the company’s stock worth $225,000 after purchasing an additional 205 shares in the last quarter. IFP Advisors Inc grew its position in Novartis by 25.7% during the 4th quarter. IFP Advisors Inc now owns 1,730 shares of the company’s stock worth $168,000 after purchasing an additional 354 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in Novartis in the fourth quarter valued at $2,601,000. Union Bancaire Privee UBP SA purchased a new stake in Novartis during the 4th quarter valued at approximately $27,000. Finally, Ascent Wealth Partners LLC raised its stake in shares of Novartis by 1.1% during the fourth quarter. Ascent Wealth Partners LLC now owns 16,203 shares of the company’s stock worth $1,577,000 after purchasing an additional 169 shares during the last quarter. 13.12% of the stock is owned by hedge funds and other institutional investors.

Novartis Trading Down 0.2 %

NVS stock opened at $109.15 on Tuesday. Novartis AG has a 52 week low of $92.35 and a 52 week high of $120.92. The company has a market cap of $223.10 billion, a price-to-earnings ratio of 18.56, a PEG ratio of 1.70 and a beta of 0.58. The company has a quick ratio of 0.84, a current ratio of 1.04 and a debt-to-equity ratio of 0.48. The business has a fifty day simple moving average of $101.69 and a 200-day simple moving average of $108.09.

Novartis (NYSE:NVS) last released its quarterly earnings data on Friday, January 31st. The company reported $1.98 EPS for the quarter, topping analysts’ consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. On average, equities research analysts expect that Novartis AG will post 8.45 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on NVS shares. Erste Group Bank restated a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. Barclays reiterated an “underweight” rating on shares of Novartis in a research report on Monday, February 3rd. StockNews.com upgraded shares of Novartis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 8th. Deutsche Bank Aktiengesellschaft upgraded Novartis from a “hold” rating to a “buy” rating in a report on Tuesday, February 4th. Finally, UBS Group restated a “neutral” rating on shares of Novartis in a report on Thursday, February 13th. Three research analysts have rated the stock with a sell rating, six have given a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $123.38.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.